The group company held the 2017 annual board of directors and the board of supervisors to review and approve the annual work report and other related proposals


Release time:

2018-05-02

On April 20, Jiang Xiaomeng, chairman of the group company, presided over the 3rd meeting of the 10th board of directors of the company, and deliberated and passed 15 proposals and reports including the 2017 work report of the board of directors and the 2017 work report of the general manager.

The general manager's report pointed out that in 2017, the company focused on the general work policy of "grasping trends, precise development, strengthening standards, improving quality, improving management, and enhancing efficiency", grasping the opportunities brought by economic structure optimization and industrial upgrading, and accelerating innovation Development, in-depth management integration, continuous improvement of management level, improvement of enterprise operation efficiency, strengthening of marketing expansion, and steady promotion of product sales growth, remarkable results have been achieved in technological innovation and technological transformation, the financial structure has been continuously improved, and the core competitiveness of enterprises has been further strengthened. The company achieved operating income of 2.827 billion yuan for the whole year, an increase of 18.81 percent over the same period last year, and realized net profit attributable to owners of the parent company of 348.4943 million yuan, an increase of 22.18 percent over the same period last year, another record high, with earnings per share of 1.01 yuan, achieving the best operating performance in the peak 60-year development process. Total assets at the end of the year were 4.176 billion yuan, an increase of 4.53 percent over the same period last year.

In 2017, with the in-depth implementation of the national "One Belt, One Road" initiative, cement staggered production was comprehensively promoted, industry environmental protection supervision was further improved, energy conservation and consumption reduction supervision became stricter, mergers and acquisitions were deepened, industry self-discipline awareness continued to increase, and the supply side of the cement industry Structural reforms are beginning to bear fruit. The national cement production remained basically stable, but the price of cement products increased significantly year-on-year, and the profitability of the industry increased significantly. The company's cement business segment seizes regional development opportunities, in-depth implementation of cost leadership strategy, through technological transformation, organizational optimization and information management, cement production costs have been effectively controlled. Daye Jianfeng organized production through reasonable arrangements, actively explored key engineering projects, seized the civilian market, timely adjusted the credit mechanism, and effectively encouraged the sales team, and achieved good business performance; Yunnan Jianfeng seized strategic opportunities and developed through multiple channels Key projects continue to expand regional market sales share, while actively responding to the self-discipline of the cement industry in southwest Yunnan, continue to promote brand building, and further enhance corporate influence, achieved the best performance since the production.

In 2017, the pharmaceutical industry achieved double-digit growth in revenue and profits. With the further improvement of living standards, the improvement of medical insurance and medical reform policies, the increase of the aging population and the liberalization of the two-child policy, the development prospects of the pharmaceutical industry for a long period of time in the future are still optimistic. During the reporting period, Jianfeng Pharmaceutical actively implemented the strategic layout according to the company's overall development plan, and made new breakthroughs in project cooperation. Peak Pharmaceuticals completed the first phase of its investment in Beihui Bio, holding a 20% stake. The introduction of Shanghai Yien's anti-tumor compound patent technology, joint venture to form a peak Yien, focusing on the research and development of new anti-tumor drugs. In January 2018, Jianfeng Pharmaceutical invested in Shanghai North Carolina and will further strengthen the research and development and base construction of intermediates and APIs. These measures have further improved the company's pharmaceutical business industry chain, further improved its new drug research and development capabilities, and further enhanced the core competitiveness of the pharmaceutical sector. Peak Pharmaceuticals also responded to changes in the pharmaceutical market by strengthening market segment management, adjusting marketing models in a timely manner, enhancing the vitality of the marketing team, and strengthening marketing efforts, resulting in faster growth in industrial sales. In addition, DPT (Deoxypodophyllotoxin), a new anti-tumor drug, has completed the preparation of phase I clinical trial plan and obtained the ethical approval of the clinical team leader unit, making preparations for the entry of phase I clinical trial cases.

In addition, Tianjin peak actively explore the international market, to ensure the steady growth of sales revenue. Jianfeng Health has made great efforts to develop the market of Chinese herbal pieces by strengthening investment promotion, innovating the network sales mode, creating regional store terminal models, and achieving a large increase in business income. While stabilizing the existing market, Jianfeng Cable Company has successfully developed central plastic tube large logarithmic cable products through the transformation of existing equipment according to customer needs.; Jianfeng International Trade seizes the opportunity of logistics industry development, reaches a long-term cooperation agreement with Shanghai Aneng Logistics, and invests in the new logistics warehouse (e-commerce logistics park), which will become a new profit growth point of Jianfeng International Trade.

During the reporting period, the company implemented in-depth management integration, comprehensively carried out the "three reductions and three improvements" activities, continued to promote organizational optimization, improved corporate operating efficiency, enhanced corporate internal vitality, and ensured the company's further healthy and stable development.

On the same day, the company also held the second meeting of the Ninth Board of Supervisors, and reviewed and approved 6 proposals and reports including the company's 2017 annual board of supervisors work report and 2017 annual financial final accounts report.